Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2191 to 2205 of 9027 results

  1. Cervical ripening ballon for the induction of labour in women who have previously undergone cesarean section

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development Reference number: GID-TA11422 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  3. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    Awaiting development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development Reference number: GID-TA11438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Clindamycin for treating bacterial vaginosis in females aged 12 and older [TSID 12127]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Differential Target Multiplexed Spinal Cord Stimulation (MT742)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  10. Spectra Optia for plasma exchange, (MT828)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  11. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MT604) (MIB268)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  12. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Budesonide orodispersible tablet for maintaining remission of eosinophilic oesophagitis in people 18 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Budesonide oral suspension for inducing and maintaining remission of eosinophilic oesophagitis in people 2 to 17 years [ID6761]

    Awaiting development Reference number: GID-TA12464 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    Awaiting development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    Awaiting development